Alpha 1-adrenoceptor mediated activation of Na/K/2Cl cotransport and K+ channels in the rat heart involves different receptor subtypes

Res Commun Mol Pathol Pharmacol. 1997 Jun;96(3):329-40.

Abstract

Involvement of receptor subtypes in the alpha 1-adrenoceptor mediated activation of Na/K/2Cl-cotransport and K+ channels was studied in isolated perfused spontaneously beating rat hearts stimulated by phenylephrine (30 mumol/l) in the presence of a beta-adrenoceptor antagonist (1 mumol/l timolol). The effects of alpha 1-adrenoceptor stimulation on K+ translocation mechanisms were studied by measuring the efflux of 86Rb+ (a potassium analogue). The effects of 50 mumol/l bumetanide (Na/K/2Cl-cotransport inhibitor) and 0.1-0.3 mmol/l 4-aminopyridine (inhibitor of K+ channels) were studied in the presence of alpha 1-adrenoceptor subtype selective antagonists. Bumetanide reduced the alpha 1-adrenoceptor mediated increase in 86Rb+ efflux by 53 +/- 16.4% (n = 14, P < 0.001) in hearts pretreated with the preferentially alpha 1B-adrenoceptor antagonist chloroethylclonidine (CEC, 10 mumol/l), and by 35 +/- 7.3% (n = 15, P < 0.001) in the presence of the preferentially alpha 1D-adrenoceptor antagonist BMY 7378 (1 mumol/l). In the presence of the preferentially alpha 1A-adrenoceptor antagonist 5-methylurapidil (10 mumol/l), however, bumetanide had no effect on the response to phenylephrine. 4-Aminopyridine reduced the phenylephrine stimulated 86Rb+ efflux in the presence of 5-methylurapidil, but the effect of the K(+)-channel blocker was eliminated in CEC treated hearts. Thus the effects of the two translocation inhibitors were influenced differently by the two subtype selective antagonists, showing that alpha 1-adrenoceptor stimulation activates a bumetanide sensitive Na/K/2Cl-cotransport mechanism in the rat heart mainly through the alpha 1A-receptor subtype while the 4-aminopyridine sensitive K+ channels, are mainly activated by the alpha 1B-adrenoceptor subtype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Bumetanide / pharmacology
  • Carrier Proteins / antagonists & inhibitors
  • Carrier Proteins / metabolism*
  • Chlorides / metabolism
  • Clonidine / analogs & derivatives
  • Clonidine / pharmacology
  • Heart / drug effects*
  • In Vitro Techniques
  • Male
  • Myocardium / metabolism
  • Phenylephrine / pharmacology
  • Piperazines / pharmacology
  • Potassium / metabolism
  • Potassium Channels / metabolism*
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, alpha-1 / metabolism*
  • Sodium / metabolism
  • Sodium-Potassium-Chloride Symporters

Substances

  • Adrenergic alpha-Antagonists
  • Carrier Proteins
  • Chlorides
  • Piperazines
  • Potassium Channels
  • Receptors, Adrenergic, alpha-1
  • Sodium-Potassium-Chloride Symporters
  • Bumetanide
  • 5-methylurapidil
  • Phenylephrine
  • chlorethylclonidine
  • Sodium
  • 4-Aminopyridine
  • BMY 7378
  • Clonidine
  • Potassium